Skip to main content
Sunday, November 15, 2026Nov 15

Purdue Pharma to stay in business as bankruptcy unfolds

FILE - In this Sept. 12, 2019, file photo, cars pass Purdue Pharma headquarters in Stamford, Conn. The company, which makes OxyContin and other drugs, filed court papers in New York on Sunday, Sept. 15 seeking Chapter 11 bankruptcy protection. (AP Photo/Frank Franklin II, File)
FILE - In this Sept. 12, 2019, file photo, cars pass Purdue Pharma headquarters in Stamford, Conn. The company, which makes OxyContin and other drugs, filed court papers in New York on Sunday, Sept. 15 seeking Chapter 11 bankruptcy protection. (AP Photo/Frank Franklin II, File)

A judge cleared the way Tuesday for OxyContin maker Purdue Pharma to stay in business while it pursues bankruptcy protection and settlement of more than 2,600 lawsuits filed against it in a reckoning over the opioid crisis.

At the first court hearing since the Chapter 11 filing late Sunday, Purdue lawyers secured permission for the multibillion-dollar company based in Stamford, Connecticut, to maintain business as usual – paying employees and vendors, supplying pills to distributors, and keeping current on taxes and insurance.

The continued viability of Purdue is a key component of the company’s settlement offer, which could be worth up to $12 billion over time.

Under the proposal, backed by about half the states, the Sackler family, which owns Purdue, would turn the company, its assets and more than $1 billion in cash reserves over to a trust controlled by the very entities suing it.

The Sacklers have also agreed to pay a minimum of $3 billion of their own money to the settlement over seven years, as well as up to $1.5 billion more in proceeds from the planned sale of their non-U.S. pharmaceutical companies.